Starling Oncology (STLNW) Stock: Why It Fell
Updated Oct 23, 3:53 AM ET · latest trade in feed Oct 22, 4:00 PM ET (Finnhub)
Updated Oct 22, 2026, 4:00 PM ET · closing price
- Latest session (Thu Oct 22): $0.02, +$0.00 (-3.20%), volume 167.7x its 50-day average.
- Earnings: latest quarter in SEC XBRL filings (ended Jun 30, 2026): diluted EPS $-0.08; revenue $161.3M, +34.6% year over year. Sources: SEC EDGAR XBRL.
Sector peers moving today (Healthcare Services):HCSG +14.19%AUNA -7.02%CELC +6.51%FRNM -6.50%DVA +5.25%
- Closed at $0.02, -3.20% vs the prior close of $0.03.
- Volume 1.01K shares, 167.7x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
Hims & Hers Health (HIMS)Teladoc Health (TDOC)Basel Medical (BMGL)LifeMD (LFMD)Airsculpt Technologies (AIRS)SBC Medical (SBC)
STLNW slides 3.2% to $0.02 on 167.7x normal volume. Closed at $0.02, -3.20% vs the prior close of $0.03. Day range $0.02–$0.02, opened at $0.02.
Why Did STLNW Stock Move Today?
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 22, 2026 — STLNW slides 3.2% to $0.02 on 167.7x normal volume
- Closed at $0.02, -3.20% vs the prior close of $0.03. Day range $0.02–$0.02, opened at $0.02.
- Volume was 1.01K shares, 167.7x its 50-day average of 6 — unusually heavy trading.
- 52-week range $0.02–$0.03; today's close sits at 0% of that range, 3.2% below the 52-week high.
Data-Driven Bull Case vs. Bear Case + Sector Peer Comparison Table
Points below restate what SEC filings and price data show. They are facts, not a recommendation.
- Annual revenue grew 27.8% in the latest fiscal year (SEC XBRL).
- Insiders made 13 open-market purchases in the last 12 months.
- Latest fiscal-year net income: loss of $60.61M.
- Share count up 9.0% in a year (dilution).
- High volatility: average daily move of 3.2% over 20 sessions.
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
Sector peers · Services-Offices & Clinics of Doctors of Medicine
| Ticker | Company | Last price | Day | Below 52w high | Avg $ volume (20d) |
|---|---|---|---|---|---|
| STLNW | Starling Oncology | $0.02 | -3.20% | 3.2% | $12 |
| HIMS | Hims & Hers Health | $29.13 | -0.27% | 42.9% | $287.58M |
| TDOC | Teladoc Health | $6.32 | +0.32% | 36.1% | $21.34M |
| BMGL | Basel Medical | $4.45 | +0.45% | 78.1% | $2.38M |
| LFMD | LifeMD | $2.17 | +1.40% | 66.3% | $1.82M |
| AIRS | Airsculpt Technologies | $1.25 | -2.34% | 89.6% | $1.42M |
| SBC | SBC Medical | $5.69 | +2.71% | 0.4% | $971.20K |
| AUNA | AUNA | $5.03 | -7.02% | 25.0% | $868.51K |
| WSTN | Westin Acquisition | $10.21 | +0.10% | 0.4% | $92.95K |
STLNW Earnings Date & EPS History
Diluted EPS by fiscal quarter, from Starling Oncology's 10-Q/10-K filings (SEC XBRL).
| Quarter ended | Diluted EPS |
|---|---|
| Jun 30, 2026 | $-0.08 |
| Mar 31, 2026 | $-0.02 |
| Sep 30, 2025 | $-0.14 |
| Jun 30, 2025 | $-0.15 |
| Mar 31, 2025 | $-0.21 |
| Sep 30, 2024 | $-0.18 |
| Jun 30, 2024 | $-0.17 |
| Mar 31, 2024 | $-0.22 |
STLNW Revenue, Net Income, Cash & Debt
- Revenue (quarter ended Jun 30, 2026): $161.28M
- Net income (quarter ended Jun 30, 2026): $-9.79M
- Cash & equivalents (as of Sep 30, 2021): $200.00K
- Long-term debt (as of Jun 30, 2026): $79.87M
STLNW Insider Buying & Form 4 Sales
In the last 12 months, SEC Form 4 filings show 13 open-market insider purchases and 12 sales of STLNW (latest: Brad Hively sold 298,853 shares on Aug 21, 2026). Full list in the insider table below.
STLNW 52-Week High & Low
STLNW's 52-week range is $0.02 to $0.03. At $0.02 it is 3.2% below the 52-week high and 0.0% above the 52-week low.
Latest STLNW SEC 8-K & 10-Q Filings
Every SEC filing by or about STLNW in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hively Brad sold 298,853 shares at $6.51 (≈$1.95M) on Aug 21, 2026
- Hively Brad sold 298,853 shares at $6.51 (≈$1.95M) on Aug 21, 2026
- Hively Brad sold 298,853 shares at $6.51 (≈$1.95M) on Aug 21, 2026
- Hively Brad sold 298,853 shares at $6.51 (≈$1.95M) on Aug 21, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
Aug 21, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Chernett Jorey bought 12,000 shares at $6.54 (≈$78.48K) on Aug 14, 2026
- Chernett Jorey bought 12,000 shares at $6.54 (≈$78.48K) on Aug 14, 2026
- Chernett Jorey bought 12,000 shares at $6.54 (≈$78.48K) on Aug 14, 2026
- Chernett Jorey bought 12,000 shares at $6.54 (≈$78.48K) on Aug 14, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $161.28M (prior year $119.80M) (+34.6% vs Jun 30, 2025)
- Net income: -$9.79M (prior year -$17.01M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.08 (prior year -$0.15) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 3.02 — Sold unregistered shares.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade STLNW
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 12, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.20% (largest 3.2%). That is a volatile stock.
- Liquidity: about 506 shares (≈$12) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.02 vs a range of $0.02–$0.03 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 13 open-market buys, 12 sales; latest: Brad Hively sold 298,853 shares on Aug 21, 2026.
- Latest filings: 8-K Sep 2, 2026; 8-K Aug 21, 2026; 10-Q Aug 6, 2026.
- Share count: 101.92M shares outstanding (Jul 30, 2026), +9.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Services-Offices & Clinics of Doctors of Medicine.
STLNW market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 22, 2026 | 0.02 | 0.02 | 0.02 | 0.02 | 1.01K |
| Oct 16, 2026 | 0.03 | 0.03 | 0.03 | 0.03 | 6 |
About Starling Oncology
Starling Oncology (STLNW) is listed on the Nasdaq and classified by the SEC under “Services-Offices & Clinics of Doctors of Medicine”. Its business address is in CERRITOS, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1799191.
STLNW board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Brad Hively | Director | Aug 24, 2026 |
| Karen Marie Johnson | Director | Jul 29, 2026 |
| Mohit Kaushal | Director | Jul 29, 2026 |
| Gabriel Ling | Director | Dec 1, 2025 |
| Growth I Gp Llc M33 | Director | Nov 20, 2025 |
| Growth I L.P. M33 | Director | Nov 20, 2025 |
| Anne Mcgeorge | Director | Jul 29, 2026 |
| Mark L Pacala | Director | Jul 29, 2026 |
| Mark Stolper | Director | Jul 29, 2026 |
| M, Llc Toi | Director | Nov 20, 2025 |
| Kimberly Jo Tzoumakas | Director | Jul 29, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Robert Ross Carter | Chief Financial Officer | May 22, 2026 |
| Kristin England | Chief Administrative Officer | Apr 23, 2026 |
| Jeffrey Langsam | Chief Clinical Officer | Apr 23, 2026 |
| Yale Podnos | Chief Medical Officer | Jul 16, 2026 |
| Daniel Virnich | Chief Executive Officer | May 22, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 21, 2026 | Brad Hively | Sale | 298,853 | $6.51 |
| Aug 21, 2026 | Brad Hively | Sale | 298,853 | $6.51 |
| Aug 21, 2026 | Brad Hively | Sale | 298,853 | $6.51 |
| Aug 21, 2026 | Brad Hively | Sale | 298,853 | $6.51 |
| Aug 14, 2026 | Jorey Chernett | Buy | 12,000 | $6.54 |
| Aug 14, 2026 | Jorey Chernett | Buy | 12,000 | $6.54 |
| Aug 14, 2026 | Jorey Chernett | Buy | 12,000 | $6.54 |
| Aug 14, 2026 | Jorey Chernett | Buy | 12,000 | $6.54 |
| Jul 21, 2026 | Jorey Chernett | Buy | 18,000 | $5.27 |
| Jul 21, 2026 | Jorey Chernett | Buy | 18,000 | $5.27 |
| Jul 21, 2026 | Jorey Chernett | Buy | 18,000 | $5.27 |
| Jul 21, 2026 | Jorey Chernett | Buy | 18,000 | $5.27 |
| Jul 14, 2026 | Yale Podnos | Sale | 5,478 | $6.35 |
| Jul 14, 2026 | Yale Podnos | Sale | 17,974 | $6.43 |
| Jul 14, 2026 | Yale Podnos | Sale | 5,478 | $6.35 |
STLNW financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $502.73M | $-60.61M | -0.54 | $-24.59M |
| Dec 31, 2024 | $393.41M | $-64.66M | -0.71 | $-26.54M |
| Dec 31, 2023 | $324.24M | $-83.07M | -0.92 | $-36.31M |
| Dec 31, 2022 | $252.48M | $152.00K | -0.21 | $-61.76M |
| Dec 31, 2021 | $203.00M | $-10.93M | -0.16 | $-32.68M |
Latest balance sheet: total assets $178.23M, total liabilities $203.15M, cash $200.00K (as of Jun 30, 2026).
STLNW earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | — |
| May 7, 2026 | 8-K Item 2.02 (results) | — |
| Mar 12, 2026 | 8-K Item 2.02 (results) | — |
| Jan 12, 2026 | 8-K Item 2.02 (results) | — |
| Nov 13, 2025 | 8-K Item 2.02 (results) | — |
| Aug 13, 2025 | 8-K Item 2.02 (results) | — |
| May 14, 2025 | 8-K Item 2.02 (results) | — |
| Mar 24, 2025 | 8-K Item 2.02 (results) | — |
| Nov 13, 2024 | 8-K Item 2.02 (results) | — |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Apr 3, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Services-Offices & Clinics of Doctors of Medicine
Hims & Hers Health (HIMS)Teladoc Health (TDOC)Basel Medical (BMGL)LifeMD (LFMD)Airsculpt Technologies (AIRS)SBC Medical (SBC)AUNA (AUNA)Westin Acquisition (WSTN)Concord Medical Services (CCM)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Space Exploration Technologies (SPCX)Meta Platforms (META)Tesla (TSLA)Apple (AAPL)Sandisk (SNDK)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on STLNW
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 22, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.